This study is testing a new treatment combination for **follicular lymphoma (FL)**, a type of cancer affecting the lymphatic system. It involves **Surovatamig (AZD0486)** and **rituximab**, compared with standard treatments chosen by doctors. The trial has two main parts: **Safety Run-in**—where different doses of the new treatment are tested to find the safest amount—and **Phase III**, which compares the new treatment with existing ones. Participants must be at least 18 years old, have a confirmed diagnosis of FL, and meet specific health criteria. **Key Points:** - The study is **global** and **randomized**, meaning participants are randomly chosen for different treatments. - It includes two parts, with the **Phase III** involving three different treatment groups. - Eligible participants should not have previously received specific lymphoma treatments and must meet certain health conditions. Participating might involve several visits and assessments to ensure safety and effectiveness. There could be potential side effects, and you should discuss risks and benefits with your doctor. Eligibility depends on specific health criteria, so not everyone can participate.